Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies

Documenti analoghi

• Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment
  di: Megumi Iwai, et al.
  Pubblicazione: (2025)
• First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects
  di: Tomoki Kojima, et al.
  Pubblicazione: (2026)
• In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers
  di: Megumi Iwai, et al.
  Pubblicazione: (2024)
• Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites
  di: Katharina Erb‐Zohar, et al.
  Pubblicazione: (2024)
• Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib
  di: Martha Gonzalez, et al.
  Pubblicazione: (2025)